BURLINGTON, Mass., March 5 /PRNewswire-FirstCall/ -- Palomar Medical
Technologies Inc (Nasdaq: PMTI) today announced that a new hand piece for the
Palomar EsteLux(TM) light-based system was shown for the first time at the
American Academy of Dermatology (AAD) meeting. The Company presented the LUX
R(TM) red light filtered hand piece, used for hair removal on all skin types,
including tanned skin, along with its other recently introduced EsteLux system
hand pieces; the LUX Y(TM) yellow light filtered hand piece for removal of
hair and pigmented lesions on lighter skin types; and the LUX G(TM) green
light filtered hand piece for vascular lesion treatments.
(Photo: http://www.newscom.com/cgi-bin/prnh/20000308/PMTILOGO )
The LUX R red light filtered hand piece expands the EsteLux's treatment
capabilities greatly. The Palomar EsteLux light-based system can now be used
even more effectively for removing hair on all skin types, as well as for
vascular and pigmented lesion treatments. With a unique combination of optics
and energy levels, the new LUX R hand piece selectively targets melanin in the
hair follicle. Now, with the addition of the LUX R hand piece, the EsteLux
system is the most versatile and economic cosmetic device on the market.
Oscar Saffold, M.D., of Cleveland, OH, commented: "I am currently working
with Palomar to develop a treatment protocol for people with dark skin
(Fitzpatrick skin type V-VI) using the Palomar EsteLux system with their new
red filtered hand piece, the LUX R. The LUX R hand piece is proving to be
safe and effective for temporary hair removal. We are currently conducting
studies to evaluate its long-term efficacy for hair reduction and for the
treatment of Pseudofolliculitis barbae (PFB)."
Pseudofolliculitis barbae is a common skin disorder that occurs primarily
in African Americans, with over 50 percent incidence within this population,
and other persons with thick, curly hair. The problem occurs when shaved
hairs grow back under the skin, producing inflammation, irritation and,
occasionally, keloidal scars. Men and women with PFB often refrain from
shaving in order to reduce the severity of their condition. Topical steroids,
antibiotics, and exfoliating agents may reduce the severity as well, but their
benefits tend to be short-lived.
Chairman and CEO, Dan Valente, commented: "The Palomar EsteLux system
joins a long tradition of excellence in research and development. This low
cost platform adds another dimension to Palomar and will continue to expand
into additional cosmetic applications. The EsteLux system is a low price hair
removal workhorse with a fast treatment mode. The combination is perfect for
physician practices and has the potential to expand the market for hair
removal."
He continued: "The extensive benefits of the EsteLux system will provide
additional revenue streams with good margins due to the thriftiness of the
instrument and ease of operation to aesthetic practices. Our extensive
research programs are coming to fruition as we introduce a series of new
products during the year 2002. We have added and continue to add trained
sales personnel and distributors, giving Palomar access to world markets."
About Palomar Medical Technologies Inc: Palomar is the leading researcher
and developer of laser/light based systems for hair removal and other cosmetic
treatments and is the first company to obtain clearance from the FDA for
"permanent hair reduction." Palomar systems have been installed in practices
worldwide, and hundreds of thousands of treatments have been performed. New
and exciting indications are being tested to further advance the hair removal
market and other cosmetic applications including fat reduction, acne treatment
and skin rejuvenation.
To get more information regarding Palomar and its products, please visit
Palomar's web site at http://www.palmed.com. Also, to continue to receive the most
up-to-date information and latest news on Palomar as it happens, sign up to
receive automatic e-mail alerts by going to the e-mail alerts page in the
Investor Relations' section of the web site.
With the exception of the historical information contained in this
release, the matters described herein contain forward-looking statements,
including but not limited to statements relating to new markets, development
and introduction of new products, and financial projections that involve risk
and uncertainties that may individually or mutually impact the matters herein,
and cause actual results, events and performance to differ materially from
such forward-looking statements. These risk factors include, but are not
limited to, results of future operations, technological difficulties in
developing or introducing new products, the results of future research, lack
of product demand and market acceptance for current and future products, the
effect of economic conditions, the impact of competitive products and pricing,
governmental regulations with respect to medical devices, including whether
FDA clearance will be obtained for future products, the results of litigation,
potential infringement of third-party intellectual property rights, and/or
other factors, which are detailed from time to time in the company's SEC
reports, including the report on Form 10-K for the year ended December 31,
2000 and the Company's quarterly reports on Form 10-Q. Readers are cautioned
not to place undue reliance on these forward-looking statements, which speak
only as of the date hereof. The company undertakes no obligation to release
publicly the result of any revisions to these forward-looking statements that
may be made to reflect events or circumstances after the date hereof or to
reflect the occurrence of unanticipated events.
Contacts:
Paul S. Weiner Rob Weir (Investors)
Palomar Medical Technologies Inc Allen & Caron Inc
781-993-2411 212-691-8087
ir@palmed.com robw@allencaron.com
SOURCE Palomar Medical Technologies Inc
 back to top
Related links:
http://www.palmed.com
Photo Notes:http://www.newscom.com/cgi-bin/prnh/20000308/PMTILOGO
PRN Photo Desk, 888-776-6555 or 212-782-2840
Company News On-Call:
http://www.prnewswire.com/comp/107555.html
CONTACT:
Paul S. Weiner of Palomar Medical
Technologies Inc, +1-781-993-2411, ir@palmed.com; or Rob Weir
(Investors) of Allen & Caron Inc, +1-212-691-8087,
robw@allencaron.com
|
